Inventor · disambiguated record
Ning Shan
Also filed as: SHAN NING
19 granted patents·11 pending applications·294 citations·filing 2008–2023
93Inventor score
Top patents by PatentIndex Score
30 records- 0198US8399023B2Crystallization method and bioavailabilityHANNA MAZEN·Filed 2010·Granted Mar 19, 2013·94 cites·28 claims
- 0297US9169279B2Crystallization method and bioavailabilityHANNA MAZEN·Filed 2012·Granted Oct 27, 2015·87 cites·9 claims
- 0397US8933057B2Crystallization method and bioavailabilityTHAR PHARMACEUTICALS INC·Filed 2013·Granted Jan 13, 2015·90 cites·28 claims
- 0489US9340565B2Crystalline formsHANNA MAZEN·Filed 2011·Granted May 17, 2016·5 cites·20 claims
- 0587US8124603B2In vivo studies of crystalline forms of meloxicamHANNA MAZEN·Filed 2009·Granted Feb 28, 2012·4 cites·25 claims
- 0682US8486927B2Crystalline forms of lamotrigineHANNA MAZEN·Filed 2008·Granted Jul 16, 2013·3 cites·14 claims
- 0781US9334296B2Crystallization method and bioavailabilityTHAR PHARMACEUTICALS INC·Filed 2013·Granted May 10, 2016·4 cites·22 claims
- 0880US11459301B2Crystalline form of s-apomorphineACLIPSE ONE INC·Filed 2019·Granted Oct 4, 2022·2 cites·18 claims
- 0976US10265309B2Sublingual opioid formulations containing naloxoneINSYS DEV CO INC·Filed 2017·Granted Apr 23, 2019·1 cites·2 claims
- 1074US8980868B2Oral forms of a phosphonic acid derivativeHANNA MAZEN·Filed 2010·Granted Mar 17, 2015·2 cites·14 claims
- 1174US8389512B2In vivo studies of crystalline forms of meloxicamHANNA MAZEN·Filed 2012·Granted Mar 5, 2013·2 cites·43 claims
- 1266US10519176B2Crystalline formsGRUENENTHAL CHEMIE·Filed 2017·Granted Dec 31, 2019·0 cites·15 claims
- 1365US10323052B2Crystallization method and bioavailabilityGRUENENTHAL CHEMIE·Filed 2017·Granted Jun 18, 2019·0 cites·20 claims
- 1464US10093691B2Crystallization method and bioavailabilityGRUENENTHAL CHEMIE·Filed 2016·Granted Oct 9, 2018·0 cites·5 claims
- 1563US10874658B2Sublingual opioid formulations containing naloxoneINSYS DEV CO INC·Filed 2019·Granted Dec 29, 2020·0 cites·16 claims
- 1662US2025262209A1Treatment of gastrointestinal diseasesACLIPSE TWO INC·Filed 2023·Application pending·0 cites
- 1759US10526358B2Crystalline formsGRUENENTHAL CHEMIE·Filed 2018·Granted Jan 7, 2020·0 cites·18 claims
- 1858US9040535B2Crystalline molecular comlpexes of tadalafilTHAR PHARMACEUTICALS INC·Filed 2013·Granted May 26, 2015·0 cites·8 claims
- 1956US2017022225A1Novel crystalline formsTHAR PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2055US2017022226A1Crystallization method and bioavailabilityTHAR PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2154US2021353613A1Treatment of neurological diseaseACLIPSE ONE INC·Filed 2019·Application pending·0 cites
- 2253US2022265635A1Treatment of neurological diseaseACLIPSE ONE INC·Filed 2019·Application pending·0 cites
- 2351US8586587B2Crystalline molecular complex of tadalafil and methylparabenHANNA MAZEN·Filed 2010·Granted Nov 19, 2013·0 cites·9 claims
- 2450US2016016982A1Crystallization method and bioavailabilityTHAR PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 2548US9682091B2Oral forms of a phosphonic acid derivativeGRUENENTHAL CHEMIE·Filed 2015·Granted Jun 20, 2017·0 cites·9 claims
- 2647US2023141988A1Pharmaceutical composition for use in the treatment of neurological diseasesACLIPSE ONE INC·Filed 2020·Application pending·0 cites
- 2747US2022313682A1Pharmaceutical Compositions of (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diolACLIPSE ONE INC·Filed 2020·Application pending·0 cites
- 2845US2024180908A1Treatment of kidney diseasesACLIPSE ONE INC·Filed 2022·Application pending·0 cites
- 2942US2016199294A1Sublingual naloxone sprayINSYS DEV CO INC·Filed 2016·Application pending·0 cites
- 3040US2017340557A1Sublingual fentanyl formulations containing a permeation enhancerINSYS DEV CO INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ning Shan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →